started · updated
Moderna and Merck report successful Phase III melanoma vaccine trial
Moderna and Merck have announced successful results from the Phase III INTerpath-001 clinical trial for an experimental mRNA-based therapeutic melanoma vaccine. The study evaluated a combination regimen consisting of a personalized mRNA therapy and the immunotherapy pembrolizumab (Keytruda) in 1,137 patients who had previously undergone surgery for high-risk cutaneous melanoma.
The trial met its primary endpoint, demonstrating statistically significant and clinically relevant improvements in recurrence-free survival and distant metastasis-free survival compared to pembrolizumab monotherapy. Unlike preventative vaccines, this therapeutic approach is designed to train the immune system to identify and eliminate remaining tumor cells following surgical removal.
This development marks a significant milestone as it is the first time an mRNA-based oncology treatment has successfully completed a Phase III trial. While full data details are pending formal scientific publication, the announcement has had a notable impact on market valuations for both biotechnology companies.
Entities
INTerpath-001 · Keytruda · Merck · Moderna · Pembrolizumab · Sociedad Española de Oncología Médica
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Melanoma originates in melanocytes, the cells that produce melanin to protect skin from ultraviolet rays. www.farodevigo.es · www.levante-emv.com · www.eldia.com
- [○ 1 SOURCE] Ultraviolet radiation from the sun and tanning beds is a primary risk factor for developing melanoma. www.eldia.com
- [● 3 SOURCES] The combination of a personalized mRNA-based therapy and pembrolizumab showed statistically significant improvements in recurrence-free survival compared to pembrolizumab alone. www.farodevigo.es · www.levante-emv.com · www.eldiario.es
- [○ 1 SOURCE] Melanoma can appear in various locations, including the eyes, mucous membranes, palms, and soles of the feet. www.eldia.com
- [● 3 SOURCES] The INTerpath-001 trial involved 1,137 patients who had already undergone surgery. www.farodevigo.es · www.levante-emv.com · www.eldiario.es
- [● 4 SOURCES] Moderna and Merck announced results from a Phase III clinical trial for an experimental melanoma vaccine. www.farodevigo.es · www.levante-emv.com · cincodias.elpais.com · www.eldiario.es
- [● 3 SOURCES] The trial evaluated a combination of an experimental mRNA-based personalized therapy and the immunotherapy pembrolizumab (Keytruda). www.farodevigo.es · www.levante-emv.com · www.eldiario.es
- [○ 1 SOURCE] The vaccine is a therapeutic vaccine designed to train the immune system to recognize and attack tumor cells. www.eldiario.es